Overview

Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This is a multicentric randomized phase III trial comparing adjuvant chemotherapy with gemcitabine versus 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFolfirinox) in patients with resected pancreatic adenocarcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

UNICANCER

Collaborator:

Canadian Cancer Trials Group

Treatments:

Folic Acid
Gemcitabine
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin